Benjamin C. Smeal - 17 Dec 2025 Form 4 Insider Report for Evoke Pharma Inc (EVOK)

Reporting relationship: Director
Issuer ticker: EVOK
Reported as of: 17 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Dec 2025, 16:00:17 UTC
Prior SEC filing: 22 May 2025
Source filing: View source filing
Reporting owner signature: /s/ Matthew J. D'Onofrio, Attorney-in-fact for Benjamin C. Smeal

Key filing fact

Benjamin C. Smeal filed Form 4 for Evoke Pharma Inc (EVOK) on 17 Dec 2025.

Key facts

This page summarizes Benjamin C. Smeal's Form 4 filing for Evoke Pharma Inc (EVOK).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 17 Dec 2025, 16:00.

Change

Previous filing in this sequence was filed on 22 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001748561 Primary reporting owner

Smeal Benjamin C.

Relationship: Director
Address: C/O EVOKE PHARMA, INC., 420 STEVENS AVENUE, SUITE 230, SOLANA BEACH
Signature: /s/ Matthew J. D'Onofrio, Attorney-in-fact for Benjamin C. Smeal
Signature date: 17 Dec 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EVOK transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -5,833
Change %: -100%
Price
Shares after: 0
Date: 17 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,833
Exercise price: $5.51
Footnotes: F1, F2

EVOK transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -1,125
Change %: -100%
Price
Shares after: 0
Date: 17 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,125
Exercise price: $3.45
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Benjamin C. Smeal is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the "Merger Agreement"), by and among the Issuer, QOL Medical, LLC ("Parent") and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.

Footnote F2

Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Company Option") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.